Senescent cells in the development of cardiometabolic disease

Andrea C. Postmus, Ines Sturmlechner, Johan W. Jonker, Jan Van Deursen, Bart van de Sluis, Janine K. Kruit

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

PURPOSE OF REVIEW: Senescent cells have recently been identified as key players in the development of metabolic dysfunction. In this review, we will highlight recent developments in this field and discuss the concept of targeting these cells to prevent or treat cardiometabolic diseases. RECENT FINDINGS: Evidence is accumulating that cellular senescence contributes to adipose tissue dysfunction, presumably through induction of low-grade inflammation and inhibition of adipogenic differentiation leading to insulin resistance and dyslipidaemia. Senescent cells modulate their surroundings through their bioactive secretome and only a relatively small number of senescent cells is sufficient to cause persistent physical dysfunction even in young mice. Proof-of-principle studies showed that selective elimination of senescent cells can prevent or delay the development of cardiometabolic diseases in mice. SUMMARY: The metabolic consequences of senescent cell accumulation in various tissues are now unravelling and point to new therapeutic opportunities for the treatment of cardiometabolic diseases.

Original languageEnglish (US)
Pages (from-to)177-185
Number of pages9
JournalCurrent opinion in lipidology
Volume30
Issue number3
DOIs
StatePublished - Jun 1 2019

Fingerprint

Cell Aging
Dyslipidemias
Insulin Resistance
Adipose Tissue
Cell Count
Inflammation
Therapeutics

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Molecular Biology
  • Genetics
  • Nutrition and Dietetics
  • Cardiology and Cardiovascular Medicine
  • Cell Biology

Cite this

Postmus, A. C., Sturmlechner, I., Jonker, J. W., Van Deursen, J., van de Sluis, B., & Kruit, J. K. (2019). Senescent cells in the development of cardiometabolic disease. Current opinion in lipidology, 30(3), 177-185. https://doi.org/10.1097/MOL.0000000000000602

Senescent cells in the development of cardiometabolic disease. / Postmus, Andrea C.; Sturmlechner, Ines; Jonker, Johan W.; Van Deursen, Jan; van de Sluis, Bart; Kruit, Janine K.

In: Current opinion in lipidology, Vol. 30, No. 3, 01.06.2019, p. 177-185.

Research output: Contribution to journalArticle

Postmus, AC, Sturmlechner, I, Jonker, JW, Van Deursen, J, van de Sluis, B & Kruit, JK 2019, 'Senescent cells in the development of cardiometabolic disease', Current opinion in lipidology, vol. 30, no. 3, pp. 177-185. https://doi.org/10.1097/MOL.0000000000000602
Postmus, Andrea C. ; Sturmlechner, Ines ; Jonker, Johan W. ; Van Deursen, Jan ; van de Sluis, Bart ; Kruit, Janine K. / Senescent cells in the development of cardiometabolic disease. In: Current opinion in lipidology. 2019 ; Vol. 30, No. 3. pp. 177-185.
@article{a2ade01f03b346b882f457e6aa42a129,
title = "Senescent cells in the development of cardiometabolic disease",
abstract = "PURPOSE OF REVIEW: Senescent cells have recently been identified as key players in the development of metabolic dysfunction. In this review, we will highlight recent developments in this field and discuss the concept of targeting these cells to prevent or treat cardiometabolic diseases. RECENT FINDINGS: Evidence is accumulating that cellular senescence contributes to adipose tissue dysfunction, presumably through induction of low-grade inflammation and inhibition of adipogenic differentiation leading to insulin resistance and dyslipidaemia. Senescent cells modulate their surroundings through their bioactive secretome and only a relatively small number of senescent cells is sufficient to cause persistent physical dysfunction even in young mice. Proof-of-principle studies showed that selective elimination of senescent cells can prevent or delay the development of cardiometabolic diseases in mice. SUMMARY: The metabolic consequences of senescent cell accumulation in various tissues are now unravelling and point to new therapeutic opportunities for the treatment of cardiometabolic diseases.",
author = "Postmus, {Andrea C.} and Ines Sturmlechner and Jonker, {Johan W.} and {Van Deursen}, Jan and {van de Sluis}, Bart and Kruit, {Janine K.}",
year = "2019",
month = "6",
day = "1",
doi = "10.1097/MOL.0000000000000602",
language = "English (US)",
volume = "30",
pages = "177--185",
journal = "Current Opinion in Lipidology",
issn = "0957-9672",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Senescent cells in the development of cardiometabolic disease

AU - Postmus, Andrea C.

AU - Sturmlechner, Ines

AU - Jonker, Johan W.

AU - Van Deursen, Jan

AU - van de Sluis, Bart

AU - Kruit, Janine K.

PY - 2019/6/1

Y1 - 2019/6/1

N2 - PURPOSE OF REVIEW: Senescent cells have recently been identified as key players in the development of metabolic dysfunction. In this review, we will highlight recent developments in this field and discuss the concept of targeting these cells to prevent or treat cardiometabolic diseases. RECENT FINDINGS: Evidence is accumulating that cellular senescence contributes to adipose tissue dysfunction, presumably through induction of low-grade inflammation and inhibition of adipogenic differentiation leading to insulin resistance and dyslipidaemia. Senescent cells modulate their surroundings through their bioactive secretome and only a relatively small number of senescent cells is sufficient to cause persistent physical dysfunction even in young mice. Proof-of-principle studies showed that selective elimination of senescent cells can prevent or delay the development of cardiometabolic diseases in mice. SUMMARY: The metabolic consequences of senescent cell accumulation in various tissues are now unravelling and point to new therapeutic opportunities for the treatment of cardiometabolic diseases.

AB - PURPOSE OF REVIEW: Senescent cells have recently been identified as key players in the development of metabolic dysfunction. In this review, we will highlight recent developments in this field and discuss the concept of targeting these cells to prevent or treat cardiometabolic diseases. RECENT FINDINGS: Evidence is accumulating that cellular senescence contributes to adipose tissue dysfunction, presumably through induction of low-grade inflammation and inhibition of adipogenic differentiation leading to insulin resistance and dyslipidaemia. Senescent cells modulate their surroundings through their bioactive secretome and only a relatively small number of senescent cells is sufficient to cause persistent physical dysfunction even in young mice. Proof-of-principle studies showed that selective elimination of senescent cells can prevent or delay the development of cardiometabolic diseases in mice. SUMMARY: The metabolic consequences of senescent cell accumulation in various tissues are now unravelling and point to new therapeutic opportunities for the treatment of cardiometabolic diseases.

UR - http://www.scopus.com/inward/record.url?scp=85065511950&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85065511950&partnerID=8YFLogxK

U2 - 10.1097/MOL.0000000000000602

DO - 10.1097/MOL.0000000000000602

M3 - Article

C2 - 30913069

AN - SCOPUS:85065511950

VL - 30

SP - 177

EP - 185

JO - Current Opinion in Lipidology

JF - Current Opinion in Lipidology

SN - 0957-9672

IS - 3

ER -